Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic, Inc. to Participate in Scientific and Industry Conferences in April ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Research analysts at William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Lundin Mining Announces New Shareholder Distribution Policy; Adjusting Quarterly Dividend to C$0.0275/Share From C$0.09/Share; Allocating Up to Around $150M Per Year in Share Buybacks; Committed to ...